Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDC Should Help Spur FDA Sunscreen Filter Review – PASS Coalition

This article was originally published in The Tan Sheet

Executive Summary

Consumers would be better equipped against harmful UV radiation if they had access to next-generation sunscreen actives mired in FDA’s time and extent application process, the Public Access to Sun Screens Coalition suggests in comments to CDC. The Personal Care Products Council also submitted comments emphasizing the importance of sunscreen use.

You may also be interested in...



Senators Push FDA For SPF Cap, Spray Sunscreen Review

Nine Democrats led by Senator Jack Reed ask FDA to resolve sunscreen issues that remain in regulatory limbo. FDA needs to clarify “misconceptions about misleadingly high SPF labels beyond 50, where the increase in UV protection is relatively small,” the senators suggest.

Council’s New “Skin Smart” Video Targets Sunscreen Myths

Council’s second “Skin Smart” episode tackles myths and misgivings among consumers that discourage sunscreen use. Aired Nov. 9, the video features three experts who reject the notion that sunscreen is only needed on sunny days or for certain skin shades while upholding the safety of sunscreen ingredients.

FDA Strengthens Sunscreen Testing And Label Requirements

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.

Topics

Related Companies

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel